Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.

Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.

PMID:
23900220
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.

Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S.

Gut. 2012 Jun;61(6):847-54. doi: 10.1136/gutjnl-2011-300865. Epub 2012 Mar 17.

PMID:
22427238
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.

PMID:
21660972
[PubMed - indexed for MEDLINE]
4.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
[PubMed - indexed for MEDLINE]
5.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160
[PubMed - indexed for MEDLINE]
6.

The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.

Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A.

Histopathology. 2012 Nov;61(5):777-87. doi: 10.1111/j.1365-2559.2012.04273.x. Epub 2012 Jul 16.

PMID:
22803799
[PubMed - indexed for MEDLINE]
7.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001. Epub 2013 May 7.

PMID:
23665275
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.

Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH.

Virchows Arch. 2009 Dec;455(6):485-94. doi: 10.1007/s00428-009-0857-0. Epub 2009 Nov 13.

PMID:
19911194
[PubMed - indexed for MEDLINE]
9.

Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.

Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF.

Br J Surg. 2009 Oct;96(10):1196-204. doi: 10.1002/bjs.6683.

PMID:
19787768
[PubMed - indexed for MEDLINE]
10.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

PMID:
18832519
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.

Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH.

Am J Surg Pathol. 2013 Oct;37(10):1532-41. doi: 10.1097/PAS.0b013e31829ab1c1.

PMID:
24025523
[PubMed - indexed for MEDLINE]
12.

KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.

Kohonen-Corish MR, Tseung J, Chan C, Currey N, Dent OF, Clarke S, Bokey L, Chapuis PH.

Int J Cancer. 2014 Jun 15;134(12):2820-8. doi: 10.1002/ijc.28619. Epub 2013 Dec 6.

PMID:
24259266
[PubMed - indexed for MEDLINE]
13.

TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.

Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.

Hum Pathol. 2007 Apr;38(4):614-20. Epub 2007 Jan 31.

PMID:
17270239
[PubMed - indexed for MEDLINE]
14.

TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.

Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S.

PLoS One. 2011;6(9):e25062. doi: 10.1371/journal.pone.0025062. Epub 2011 Sep 20.

PMID:
21949851
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F.

Cancer Res. 2008 Oct 15;68(20):8541-6. doi: 10.1158/0008-5472.CAN-08-1171.

PMID:
18922929
[PubMed - indexed for MEDLINE]
Free Article
16.

CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.

Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, Hooker CM, Morgan R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N.

Clin Cancer Res. 2012 Sep 1;18(17):4743-52. doi: 10.1158/1078-0432.CCR-12-0707. Epub 2012 Jul 23.

PMID:
22825585
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S.

PLoS One. 2008;3(11):e3698. doi: 10.1371/journal.pone.0003698. Epub 2008 Nov 12.

PMID:
19002263
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.

BMC Cancer. 2011 Aug 10;11:344. doi: 10.1186/1471-2407-11-344.

PMID:
21827707
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.

Rhee YY, Kim MJ, Bae JM, Koh JM, Cho NY, Juhnn YS, Kim D, Kang GH.

Ann Surg Oncol. 2012 Oct;19(11):3441-8. doi: 10.1245/s10434-012-2410-7. Epub 2012 May 23.

PMID:
22618722
[PubMed - indexed for MEDLINE]
20.

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.

Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A.

Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1. doi: 10.1053/j.gastro.2008.02.094. Epub 2008 Mar 8.

PMID:
18435933
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk